If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
337
results.
Updated on
21/08/2026 [07:27:00]
Results 225 to 250 of 337
Absstract of: US20260194516A1
0000 The invention is based on a novel technology to identify inflammatory responsive elements (IREs) in a mesenchymal stromal cell (MSC) culture that allowed for the development of biomarkers, in particular CD55, CD146, CD271 and MSCA-1, or combinations thereof. The biomarkers of the invention are indicative for an immunomodulatory activity of an MSC. Consequently, the present invention pertains a first aspect, to a method for determining a presence or absence of an immunomodulatory activity of a mesenchymal stromal cell (MSC). Furthermore, in a second aspect, a method for the manufacture of an immunomodulatory preparation derived from an MSC with immunomodulatory activity is disclosed. In a third and fourth aspect, the invention pertains to an immunomodulatory preparation derived from an MSC with immunomodulatory activity and its medical use. In further aspects, the invention also pertains to methods for identifying an immunomodulatory population and an immunomodulatory subpopulation of MSCs with a known presence and/or expression of a biomarker respectively, and to an agent for determining a presence or absence of an immunomodulatory activity of an MSC.
Absstract of: US20260191829A1
0000 Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.
Absstract of: US20260191820A1
0000 Provided herein are methods and compositions utilizing a urolithin A agent and a fisetin agent for treatment of neurodegenerative diseases.
Absstract of: US20260194540A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
Absstract of: US20260193314A1
A ratiometric fluorescent sensor constructed based on a G protein-coupled receptor and its construction method are provided. It is discovered that by introducing a mutation at the same amino acid site (the third amino acid of the N-terminal linker) on a GRAB sensor, the GRAB sensor can be endowed with excitation ratiometric properties. The sensor with excitation ratiometric properties have high pH sensitivity, are not limited by the sensor's own expression level or external hardware conditions, maintain high stability of fluorescence brightness, can minimize fluorescence interference caused by motion, can sensitively detect neurotransmitter release, and have the potential for in vivo quantitative detection of neurotransmitter concentration.
Absstract of: US20260194539A1
A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Absstract of: WO2026144428A1
Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.
Absstract of: AU2024411321A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Absstract of: WO2026146226A1
The present invention relates to means and methods relevant to assessing the risk of developing and/or aiding in the diagnosis of an inflammatory vascular condition and/or a multimorbidity comprising a neurological autoimmune disease and an inflammatory vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having a neurological autoimmune disease. The present invention also relates to assessing the risk of developing and/or aiding in the diagnosis of a neurological autoimmune disease and/or a multimorbidity comprising a neurological autoimmune disease and a vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having an inflammatory vascular condition.
Absstract of: WO2024263558A1
Described are dual transporters and methods of making and using the dual transporters. The dual transporters bind to a blood brain barrier transport protein and a second protein that is expressed on the luminal surface of the blood brain barrier or is a brain retention protein. The dual transporters improve delivery to the central nervous system.
Absstract of: WO2025046049A1
The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.
Absstract of: KR20260106296A
본 발명은 다중 바이오마커를 이용한 치매 진단에 관한 것으로, 특히 동일한 질병인 치매에 대하여 베타 아밀로이드나 타우 등 다양한 바이오마커를 동시에 측정하여 치매를 진단하는 방법에 관한 것이다. 본 발명은 혈액, 뇌척수액 또는 기타 생체 샘플에서 다수의 바이오마커를 측정하여 치매의 존재를 보다 정확하게 진단할 수 있는 방법에 관련된다.
Absstract of: KR20260106387A
본 발명은 퇴행성 뇌질환, 특히 알츠하이머병, 파킨슨병, 헌팅턴병 및 기타 신경퇴행성 질환의 진단 시스템에 관한 것이다. 구체적으로는 다중 바이오마커를 이용하여 퇴행성 뇌질환의 진단을 수행하며, 이를 인공지능 알고리즘을 통해 정확히 분석하여 보다 효과적이고 신속한 진단을 수행할 수 있는 시스템을 제공하는 기술에 관한 것이다.
Absstract of: WO2020172645A1
Provided is a system for detecting a user of a bathroom. The system comprises at least one sensor coupled to a bathroom use analysis device, where the sensor generates data that can be used to detect and/or identify the user. Also provided is a method of detecting a user of a bathroom. The method comprises analyzing data generated by the sensor in the above system to detect and/or identify the user.
Absstract of: CN122344252A
本申请公开了一种p‑Tau231特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域。本申请抗体重链CDRH1‑CDRH3的氨基酸序列分别依次如SEQ ID NO：1‑SEQ ID NO：3所示，轻链CDRL1的氨基酸序列如SEQ ID NO：4所示，轻链CDRL2的氨基酸序列为QA，轻链CDRL3的氨基酸序列如SEQ ID NO：5所示。本申请还提供了靶向p‑Tau231的抗体、检测p‑Tau231的化学发光试剂盒。本申请抗体亲和力高、灵敏度高且生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域，可用于阿尔茨海默症的辅助诊断。
Absstract of: CN122344254A
0001 本发明提供了一种识别ApoE的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK31，包括HZK31‑B0002、HZK31‑B0005、HZK31‑B0007、HZK31‑B0011。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。
Absstract of: KR20260105078A
본 발명은 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 하나의 질병에 대하여 다중 바이오마커를 이용하여 정밀하고 정확하게 현장에서 진단할 수 있는 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것이다.
Absstract of: KR20260104904A
0001a 본 발명은 펩타이드 리간드 코팅 팁에 관한 것으로, 특히 광산화 증폭 면역 분석 기기에 사용되는 펩타이드 리간드를 안정적이고 효율적으로 코팅할 수 있는 팁을 제공하는 것이다.
Absstract of: KR20260104836A
0001a 본 발명은 2채널 고감도 면역분석 자동화 기기에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 퇴행성 뇌질환과 심혈관 질환을 동시에 현장에서 진단할 수 있는 2채널 고감도 면역분석 자동화 기기에 관한 것이다.
Absstract of: CN122326739A
本发明公开了血清标志物miR‑206在制备阿尔茨海默病诊断产品中的应用，本发明首次将血清标志物miR‑206用于阿尔茨海默病的有效诊断与辅助诊断中，并且具有极高的诊断性能。本发明为开发稳定、可靠的阿尔茨海默病即时检测试剂盒或自动化化学发光检测系统等体外诊断产品奠定了技术与数据基础，具有推动阿尔茨海默病早期筛查、辅助诊断从依赖复杂影像和脑脊液检查向便捷、无创的血液检测转变的重大临床应用前景。
Absstract of: CN122325600A
本发明提供一种用于诊断阿尔茨海默症的抗体及其制备方法。申请人通过研究发现了几组抗体对，利用双抗夹心法检测p‑Tau217，亲和力和灵敏度高，对阿尔茨海默症的诊断具有十分积极的意义。
Absstract of: WO2025120373A1
Methods of determining the potency of a human neonatal Fc receptor (FcRn) antagonist composition in inhibiting the binding of human IgG to FcRn using a competition binding assay are provided. Kits for carrying out said methods, and methods of manufacturing a FcRn antagonist composition comprising said methods of determining potency are also provided.
Absstract of: CN122330436A
0001 本发明公开了一种外泌体检测方法，包括将生物样本与裂解液混合得到样本裂解液的步骤；所述裂解液与生物样本的体积比为1:1。使用本发明中的提取外泌体和直接裂解两种方法检测TSG101和PDCD6IP浓度，所得检测结果具有较高的一致性，即本方法在提高效率的同时还具有较高的准确性。
Absstract of: CN122330416A
0001 本发明属于生物技术领域，公开了血清淀粉样P物质（SAP）作为生物标志物在制备诊断或预测射血分数保留型心力衰竭合并心房颤动（HFpEF合并AF）的产品中的应用。本发明通过构建HFpEF合并AF动物模型发现，SAP在动物模型中表达水平显著升高；在临床患者血浆样本中验证发现，HFpEF合并AF患者血浆中的SAP水平较对照组显著升高。因此，本发明通过对血浆中SAP进行定量检测，可实现对HFpEF合并AF的预测或诊断。
Nº publicación: CN122325602A 03/07/2026
Applicant:
通化师范学院
Absstract of: CN122325602A
本发明涉及免疫学技术领域，具体公开了一种抗Tau单克隆抗体及其应用，其重链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:1、2和3所示的氨基酸序列；且其轻链的三个CDR区的氨基酸序列分别具有如SEQ ID NO:4、5和6所示的氨基酸序列。本发明提供的抗Tau单克隆抗体能够结合Tau蛋白N端投射区域，特异性识别Tau蛋白N端Thr95/Thr101磷酸化修饰位点，能用于人脑样本中Tau蛋白及其病理相关组分的免疫印迹检测，能用于转基因动物和人脑组织样本中Tau病理结构的组织学检测以及Tau蛋白相关疾病中的病理分期的研究。
BOPI
Electronic site
